Pablo Cagnoni, Rubius CEO
March 15, 2021 07:30 AM EDTUpdated March 19, 03:06 PM
R&D

Ru­bius chief lays out the first hu­man da­ta on their lead red cell drug in a come­back play. And the stock sky­rock­ets

John Carroll

Editor & Founder

Ru­bius $RU­BY CEO Pablo Cagnoni is fac­ing a crit­i­cal and close­ly-watched test to­day.

Al­most ex­act­ly a year af­ter watch­ing the biotech’s shares rout­ed af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Can Bill An­der­son save Bay­er?

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times